Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02267343 | Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer | completed | Phase 3 | 493 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 3, 2024 | clinicaltrials |
| NCT02746796 | Study of ONO-4538 in Gastric Cancer | completed | Phase 2 / Phase 3 | 680 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 3, 2024 | clinicaltrials |
| NCT03006705 |
| Study of Adjuvant ONO-4538 With Resected Gastric Cancer |
| completed |
| Phase 3 |
| 800 |
| Ono Pharmaceutical Co., Ltd.INDUSTRY |
| 4 |
| May 3, 2024 |
| clinicaltrials |
| NCT03324802 | Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery | completed | Phase 3 | 107 | Mayo ClinicOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT01468883 | The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation | completed | Phase 3 | 256 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2024 | clinicaltrials |
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | completed | Phase 3 | 372 | Kyowa Kirin, Inc.INDUSTRY | 11 | Apr 25, 2024 | clinicaltrials |
| NCT03217812 | A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | completed | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT00653068 | Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System | completed | Phase 3 | 70 | Children's Oncology GroupNETWORK | 3 | Apr 23, 2024 | clinicaltrials |
| NCT05629949 | A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer | completed | Phase 3 | 474 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06179732 | Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities | completed | Phase 3 | 2,400 | The Mentor InitiativeOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | completed | Phase 3 | 260 | Denovo Biopharma LLCINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT01751997 | Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors | completed | Phase 2 / Phase 3 | 116 | Byung-Sik ChoOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT01827553 | Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy(CONKO-007) | completed | Phase 3 | 830 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05021263 | Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery? | completed | Phase 3 | 90 | Thomas Jefferson UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT01942135 | Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | completed | Phase 3 | 521 | PfizerINDUSTRY | 17 | Apr 4, 2024 | clinicaltrials |
| NCT02395016 | A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer | completed | Phase 3 | 90 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT03959241 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)(1703/1801) | completed | Phase 3 | 431 | Medical College of WisconsinOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03866993 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 350 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03940196 | Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | completed | Phase 3 | 540 | NovoCure Ltd.INDUSTRY | 13 | Mar 29, 2024 | clinicaltrials |
| NCT04177108 | A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 3 | 242 | Hoffmann-La RocheINDUSTRY | 37 | Mar 27, 2024 | clinicaltrials |
| NCT04613674 | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | completed | Phase 3 | 441 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT00381680 | Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | completed | Phase 3 | 275 | Children's Oncology GroupNETWORK | 4 | Mar 26, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT01924533 | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | completed | Phase 3 | 525 | AstraZenecaINDUSTRY | 4 | Mar 22, 2024 | clinicaltrials |
| NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | completed | Phase 3 | 5,351 | NSABP Foundation IncNETWORK | 2 | Mar 21, 2024 | clinicaltrials |
| NCT02145871 | A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy | completed | Phase 3 | 282 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT03781154 | Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors | completed | Phase 3 | 31 | University of Colorado, DenverOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT00877656 | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma | completed | Phase 2 / Phase 3 | 21 | Emergent BioSolutionsINDUSTRY | 0 | Mar 18, 2024 | clinicaltrials |
| NCT00295646 | Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | completed | Phase 3 | 1,803 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 2 | Mar 15, 2024 | clinicaltrials |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(MONALEESA-7) | completed | Phase 3 | 672 | Novartis PharmaceuticalsINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT03337724 | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer(IPATunity130) | completed | Phase 3 | 579 | Hoffmann-La RocheINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT01822314 | Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer(ETNA) | completed | Phase 3 | 632 | Fondazione MichelangeloOTHER | 6 | Mar 7, 2024 | clinicaltrials |
| NCT02620280 | Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1(NeoTRIPaPDL1) | completed | Phase 3 | 278 | Fondazione MichelangeloOTHER | 7 | Mar 6, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT02997501 | T790M Plasma Testing Methodology Comparison and Clinical Validation(ADELOS) | completed | Phase 3 | 256 | AstraZenecaINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00304070 | Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor | completed | Phase 3 | 78 | Children's Oncology GroupNETWORK | 4 | Feb 28, 2024 | clinicaltrials |
| NCT04103398 | TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma(TREAT) | completed | Phase 3 | 162 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05338723 | Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients | completed | Phase 3 | 50 | Tanta UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05726097 | Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure | completed | Phase 3 | 147 | Region SkaneOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02013648 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | completed | Phase 3 | 204 | University of UlmOTHER | 2 | Feb 23, 2024 | clinicaltrials |
| NCT00630032 | Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer(TavIx) | completed | Phase 3 | 762 | UNICANCEROTHER | 3 | Feb 21, 2024 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT03265574 | PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?(PROACT) | completed | Phase 3 | 111 | South Tees Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03388346 | 68Ga PSMA in Preprostatectomy Patients | completed | Phase 2 / Phase 3 | 22 | Michael Graham PhD, MDOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT01802814 | International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 | completed | Phase 3 | 700 | Charite University, Berlin, GermanyOTHER | 17 | Feb 9, 2024 | clinicaltrials |
| NCT04644822 | Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. | completed | Phase 3 | 100 | Centre for Probe Development and CommercializationOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05024253 | Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements. | completed | Phase 3 | 48 | Children's Cancer Hospital Egypt 57357OTHER | 1 | Feb 7, 2024 | clinicaltrials |
Data updated 24 days agoSource updated May 3, 2024source: clinicaltrials